Praveen Mannam, MD
Pulmonary Disease · Greensboro, NCNPI 1316113897
Payments from drug & device makers
Across 317 payments — averaging $35.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$3K
- Genentech USA, Inc.$3K
- GSK$835
- Boehringer Ingelheim$629
- AstraZeneca$611
- United Therapeutics Corporation$414
- plus $3K from 27 others
What the payments were for
- Consulting fees$2,71034%
- Food & beverage$5,26465%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 3 | $3,307 |
| Genentech USA, Inc. | 18 | $3,075 |
| GSK | 64 | $835 |
| Boehringer Ingelheim | 36 | $629 |
| AstraZeneca(2 entities) | 39 | $611 |
| United Therapeutics Corporation | 20 | $414 |
| Novartis | 18 | $276 |
| Sanofi | 11 | $246 |
| Insmed, Inc. | 13 | $232 |
| Actelion Pharmaceuticals US, Inc. | 11 | $213 |
| Merck | 13 | $210 |
| Grifols USA, LLC | 8 | $156 |
| Mylan Specialty L.p. | 10 | $152 |
| Regeneron Healthcare Solutions, Inc. | 6 | $151 |
| AbbVie(2 entities) | 7 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Philips North America LLC | 5 | $87 |
| Mallinckrodt Hospital Products Inc. | 4 | $76 |
| Janssen Research & Development, LLC | 1 | $67 |
| Genentech, Inc. | 1 | $66 |
| Sunovion Pharmaceuticals Inc. | 6 | $64 |
| Viatris Specialty LLC | 3 | $54 |
| Amgen | 2 | $45 |
| Shionogi Inc | 2 | $43 |
| Verona Pharma, Inc. | 2 | $38 |
| Johnson & Johnson | 1 | $32 |
| La Jolla Pharmaceutical Company | 2 | $31 |
| Baxter Healthcare | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Inogen, Inc. | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Quidel Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOLAIR$2,710
How this compares
$11,386 in reported general payments places this provider in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 150 | $2,294,672 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 365 | $297,987 |
| Tyvaso DpiTreprostinil | 11 | $273,575 |
| Dupixent PenDupilumab | 38 | $173,492 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $117,423 |
| Pirfenidone | 63 | $80,720 |
| Breo ElliptaFluticasone/Vilanterol | 130 | $65,645 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $54,739 |
| XolairOmalizumab | 20 | $48,271 |
| NucalaMepolizumab | 13 | $47,684 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 76 | $41,661 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $35,223 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $30,363 |
| Spiriva RespimatTiotropium Bromide | 33 | $27,139 |
| EliquisApixaban | 16 | $16,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $629 | $2,357,034239 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta | $835 | $452,977584 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $611 | $85,101172 claims |
| Genentech, Inc.Xolair | $66 | $48,27120 claims |
| MerckDulera | $210 | $3,43312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Greensboro
- Murali RamaswamyGreensboro$2M
- Michael WertGreensboro$412K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Mikell JarrattGastonia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.